Evidence map›Paper›PMID 35906623›Full record

Trial reportRadiation oncology (London, England)2022

Dose escalation based on

Hongcheng Zhu, Qiufang Liu, Hao Xu, Miao Mo, Zezhou Wang, Kui Lu, Jialiang Zhou, Junqiang Chen, Xiangpeng Zheng, Jinjun Ye and 11 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03790553 (A Phase III Study of Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03790553 phase3unknown statusnot on this map

A Phase III Study of Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

TypeinterventionalSponsorFudan UniversityRan2018 to 2025Enrolled646ConditionsEsophageal Squamous Cell CarcinomaArmsRadiotherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Hongcheng Zhu *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qiufang Liu *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hao Xu *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Miao MoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zezhou WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Kui LuDepartment of Radiation Oncology, Taizhou Second People's Hospital, Taizhou, Jiangsu, China.
Jialiang ZhouDepartment of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Junqiang ChenDepartment of Radiation Oncology, Fujian Cancer Hospital, Fuzhou, China.
Xiangpeng ZhengDepartment of Radiation Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Jinjun YeDepartment of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, China.
Xiaolin GeDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Honglei LuoDepartment of Radiation Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Qi LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiaying DengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dashan AiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shengnan HaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Junhua ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
I Hsuan TsengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shaoli SongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yun ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. chenyun_qz@fudan.edu.cn.
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. kuaile_z@fudan.edu.cn.
Shanghai Medical College of Fudan University · CNShanghai Institute of Hematology · CNFudan University Shanghai Cancer Center · CNFudan University · CNFujian Provincial Cancer Hospital · CNJiangnan University · CNJiangsu Cancer Hospital · CNNanjing Medical University · CNSecond People’s Hospital of Huai’an · CNTaizhou Second People's Hospital · CN

Funding

Beijing Bethune Charitable Foundation flzh202119Chinese Society of Clinical Oncology Y-Young2020-0003National Natural Science Foundation of China 82102827, 81872454
6 · The paper itself

Abstract

introductionDefinitive chemoradiotherapy has established the standard non-surgical treatment for locally advanced esophageal cancer. The standard dose of 50-50.4 Gy has been established decades ago and been confirmed in modern trials. The theorical advantage of better local control and technical advances for less toxicity have encouraged clinicians for dose escalation investigation. METHODS AND ANALYSIS: The ESO-Shanghai 12 trial is a prospective multicenter randomized phase 3 study in which patients are randomized to either 61.2 Gy or 50.4 Gy of radiation dose by PET response. Both groups undergo concurrent chemoradiotherapy with paclitaxel/cisplatin regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles. Patients with histologically confirmed ESCC [T1N1-3M0, T2-4NxM0, TxNxM1 (Supraclavicular lymph node metastasis only), (AJCC Cancer Staging Manual, 8th Edition)] and without any prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer will be eligible. The primary endpoints included overall survival in PET/CT non-responders (SUV ETHICS AND DISSEMINATION: This trial has been approved by the Fudan University Shanghai Cancer Center Institutional Review Board. Trial results will be disseminated via peer reviewed scientific journals and conference presentations. Trial registration The trial was initiated in 2018 and is currently recruiting patients. Trial registration number NCT03790553.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaChemoradiotherapyChinaFluorodeoxyglucose F18HumansPositron Emission Tomography Computed TomographyProspective StudiesRadiopharmaceuticalsTreatment OutcomeFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID35906623
PMCPMC9338557
OpenAlexW4288709685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.